Though Advent did not provide any financial details or the percentage of the stake to be acquired, sources in know of the matter said the deal gives RA Chem Pharma an enterprise value of around Rs 1,000 crore. They also said the PE firm is acquiring up to 60 per cent stake in the pharmaceutical … Read more
In return for opening its dairy markets and slashing tariffs on farm goods as the two sides seek to shore up a new trade deal, three sources said. India accounts for 40% of US generic drug imports, including the anti-malarial hydroxychloroquine, touted by US President Donald Trump in the fight against the coronavirus. To win … Read more
If all goes well with either of two antibody therapies it is testing. Lilly is also doing preclinical studies of a third antibody treatment for the illness caused by the new coronavirus that could enter human clinical trials in the coming weeks, Chief Scientific Officer Daniel Skovronsky said in an interview. Lilly has already launched … Read more
The UK-based firm informally contacted Gilead last month to gauge its interest in a possible tie-up, the people said, asking not to be identified because the details are private. AstraZeneca didn’t specify terms for any transaction, they said. While Gilead has discussed the idea with advisers, no decisions have been made on how to proceed … Read more
Export curbs were imposed on paracetamol and formulations made from the compound on March 3 by the government to shore up domestic supplies amid the threat of the coronavirus pandemic. On April 17, the government removed the curbs on shipments of formulations made from paracetamol. Now, the Directorate General of Foreign Trade (DGFT) has removed … Read more
In a positive for Biocon, US drug regulator USFDA has accepted a biologics licence application by biopharmaceutical major and partner Mylan for a proposed biosimilar to treat advanced colon or rectal cancer. The application seeks approval of biosimilar bevacizumab for treatment of patients with metastatic colorectal cancer in addition to other ailments. “Once approved, our … Read more
In a first, pharma major Wockhardt has got the nod from the Drug Controller General of India (DCGI) for two new antibiotic medicines, which it plans to launch in the Indian market over the next few months. In the last 15 years, there has been no new antibiotic launch in this category (gram-positive bacterial infections) … Read more
Car sales down, consumers muted, banks struggling, public spending increasing, IT and pharma facing global headwinds. Choice gets more confusing than ever !